DURHAM … Trimeris (Nasdaq: TRMS) and its development partner, Roche, will open physician enrollment for the U.S. Early Access Program for Fuzeon, an HIV drug in development, will open Monday, Aug. 19.

This program, running parallel with other controlled Fuzeon clinical trials, will make the drug available in the near term for a limited number of additional patients with advanced HIV disease. Study drug will be made available across all participating countries, including the U.S. and Europe, beginning in early October.

Fuzeon is the most clinically advanced in an investigational class of HIV drugs known as fusion inhibitors. Unlike existing anti-HIV drugs, which target viral enzymes involved in replication of the virus, Fuzeon is designed to block HIV from fusing with a host cell.

Patients will be enrolled in the U.S. Fuzeon Early Access Program through physicians only. Patients enrolled in this program will be tracked for drug safety. Upon successful completion of all required regulatory documentation, contracts and the site initiation visit, physicians may be able to enroll up to five patients, depending upon the number of patient slots available, as patient enrollment progresses during this program.

Trimeris: www.trimeris.com

U.S. Early Access Program: www.T20EAP.com